Cefepime hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Cefepime hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
65
Registered trials
18
Result records
68
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Cefepime hydrochloride can convert its Small molecule drug profile and PBPs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Cefepime hydrochloride (query alias: cefepime taniborbactam) |
|---|---|
| Modality / target | Small molecule drug; PBPs; PBPs inhibitors, Cell wall inhibitors |
| Highest global status | Approved |
| Originator | Bristol Myers Squibb Co. |
| Active developers | Bristol-Myers Squibb Srl, Shinpoong Pharmaceutical Co., Ltd., Baxter Healthcare Corp. |
The MCP disease footprint includes Bronchiectasis, Cholangitis, Cholecystitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06954129 | Phase 4 | Recruiting | 750 | Serum Cystatin C Concentration |
| NCT07484633 | Phase 4 | Not yet recruiting | 110 | Proportion of patients achieving PK/PD index: 100% fT>MIC (Ctrough >MIC) |
| NCT06406114 | Phase 2 | Recruiting | 300 | Proportion of participants with confirmed culprit cephalosporin allergy |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial
Phase 3; n=614; evaluation: Positive. Reported fields: Composite endpoint(clinical and microbiological success) = 72.0 % ; Composite endpoint(clinical and microbiological success) = 82.0 % ; Composite endpoint(clinical and microbiological success) = 61.0 %
Tough Nut to Crack: Baseline White Blood Cell Count Modifies the Effect of Piperacillin-Tazobactam vs Cefepime on Mortality in the ACORN Trial
Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: death: OR = 0.51, P-Value = < 0.001; death: OR = 0.51, P-Value = < 0.001
An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Study To Determine The Impact Of Serial Procalcitonin On Improving Antimicrobial Stewardship And On The Efficacy, Safety, And Tolerability Of Imipenem-Cilastatin-Relebactam Plus/Minus Vancomycin Or Linezolid Versus Standard Of Care Antipseudomonal Beta-Lactams Plus/Minus Vancomycin Or Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer
Phase 2; n=100; evaluation: not stated. Reported fields: -; -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Cefepime hydrochloride addresses Bronchiectasis, Cholangitis, Cholecystitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 68 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PBPs records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-12-11 | Everest Medicines Announces Commercialization Service Agreement with Hasten | Approved | Financial terms not disclosed |
| 2025-11-24 | McKesson to distribute Iterum Therapeutics' ORLYNVAH for uUTIs | Approved | Financial terms not disclosed |
| 2025-08-14 | Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic | Phase 1 | US$325.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
